The Annual Report 2025 published did not contain the auditor's report. This has been corrected in this version.
TURKU, FINLAND / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), announces a correction to the company announcement of its Annual Report 2025, originally published on 4 March 2026 at 09:15 EET. An updated version of the Annual Report 2025 with the full auditor's report has been included as an attachment to this announcement.
The English version of Annual Report is available as a PDF file attached to this release and on the company's website at https://faron.com/investors/reports-and-presentations/. Also the Finnish language version of the Financial Statements is available as a PDF file attached to this release and on the company's website at https://faron.fi/sijoittajat/raportit-esitykset/.
Faron Pharmaceuticals Ltd
Board of Directors
For more information please contact:
IR Partners, Finland
(Media)
Kare Laukkanen
Phone: +358 50 553 9535
E-mail: kare.laukkanen@irpartners.fi
FINN Partners, US
(Media)
Alyssa Paldo
Phone: +1 847 791-8085
E-mail: alyssa.paldo@finnapartners.com
Cairn Financial Advisers LLP, Nominated Adviser and Broker
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
About BEXMAB
The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment.
About Bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments by targeting Clever-1, a receptor on immunosuppressive macrophages and malignant blasts. By inhibiting Clever-1, bexmarilimab reprograms the tumor microenvironment to ignite a potent anti-tumor immune response.
About Faron Pharmaceuticals Ltd.
Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient's own immune system. The Company's lead asset bexmarilimab is currently being investigated in multiple clinical trials as a potential therapy for patients with hematological malignancies and solid tumors in combination with other standard treatments.
Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Faron Pharmaceuticals. In addition, even if the actual results or development of Faron Pharmaceuticals are consistent with the forward-looking statements contained in this press release, those results or developments of Faron Pharmaceuticals may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Faron Pharmaceuticals as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Faron Pharmaceuticals could be affected by, among other things, uncertainties and delays involved in the development of product candidates, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, inflation, changes in tariff policies, political or macroeconomic developments, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Faron Pharmaceuticals is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
THE NEW SHARES ISSUED IN THE RIGHTS OFFERING WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES, AND MAY NOT BE OFFERED, SOLD OR TRANSFERRED, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES.
Attachments
Faron Tilinpäätös 2025 040326
Faron Annual Report 2025 040326
SOURCE: Faron Pharmaceuticals
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/correction-faron-pharmaceuticals-ltds-annual-report-2025-published-1143572
